BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 11023194)

  • 1. Induction of melanoma-associated antigen systemic immunity upon intratumoral delivery of interferon-gamma retroviral vector in melanoma patients.
    Fujii S; Huang S; Fong TC; Ando D; Burrows F; Jolly DJ; Nemunaitis J; Hoon DS
    Cancer Gene Ther; 2000 Sep; 7(9):1220-30. PubMed ID: 11023194
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Granulocyte-macrophage-colony-stimulating factor added to a multipeptide vaccine for resected Stage II melanoma.
    Weber J; Sondak VK; Scotland R; Phillip R; Wang F; Rubio V; Stuge TB; Groshen SG; Gee C; Jeffery GG; Sian S; Lee PP
    Cancer; 2003 Jan; 97(1):186-200. PubMed ID: 12491520
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Melanoma-associated antigens as messenger RNA detection markers for melanoma.
    Sarantou T; Chi DD; Garrison DA; Conrad AJ; Schmid P; Morton DL; Hoon DS
    Cancer Res; 1997 Apr; 57(7):1371-6. PubMed ID: 9102226
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alternative roles for interferon-gamma in the immune response to DNA vaccines encoding related melanosomal antigens.
    Wolchok JD; Srinivasan R; Perales MA; Houghton AN; Bowne WB; Blachere NE
    Cancer Immun; 2001 Aug; 1():9. PubMed ID: 12747770
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and immunological evaluation of patients with metastatic melanoma undergoing immunization with the HLA-Cw*0702-associated epitope MAGE-A12:170-178.
    Bettinotti MP; Panelli MC; Ruppe E; Mocellin S; Phan GQ; White DE; Marincola FM
    Int J Cancer; 2003 Jun; 105(2):210-6. PubMed ID: 12673681
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HLA-independent heterogeneity of CD8+ T cell responses to MAGE-3, Melan-A/MART-1, gp100, tyrosinase, MC1R, and TRP-2 in vaccine-treated melanoma patients.
    Reynolds SR; Celis E; Sette A; Oratz R; Shapiro RL; Johnston D; Fotino M; Bystryn JC
    J Immunol; 1998 Dec; 161(12):6970-6. PubMed ID: 9862732
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I trial of interferon-gamma (IFN-gamma) retroviral vector administered intratumorally to patients with metastatic melanoma.
    Nemunaitis J; Fong T; Robbins JM; Edelman G; Edwards W; Paulson RS; Bruce J; Ognoskie N; Wynne D; Pike M; Kowal K; Merritt J; Ando D
    Cancer Gene Ther; 1999; 6(4):322-30. PubMed ID: 10419050
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular detection of tumor-associated antigens shared by human cutaneous melanomas and gliomas.
    Chi DD; Merchant RE; Rand R; Conrad AJ; Garrison D; Turner R; Morton DL; Hoon DS
    Am J Pathol; 1997 Jun; 150(6):2143-52. PubMed ID: 9176405
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of melanoma-associated antigens in melanoma cell cultures.
    Urosevic M; Braun B; Willers J; Burg G; Dummer R
    Exp Dermatol; 2005 Jul; 14(7):491-7. PubMed ID: 15946236
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of differentiation melanoma-associated antigen genes is associated with favorable disease outcome in advanced-stage melanomas.
    Takeuchi H; Kuo C; Morton DL; Wang HJ; Hoon DS
    Cancer Res; 2003 Jan; 63(2):441-8. PubMed ID: 12543800
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Helper T-cell responses and clinical activity of a melanoma vaccine with multiple peptides from MAGE and melanocytic differentiation antigens.
    Slingluff CL; Petroni GR; Olson W; Czarkowski A; Grosh WW; Smolkin M; Chianese-Bullock KA; Neese PY; Deacon DH; Nail C; Merrill P; Fink R; Patterson JW; Rehm PK
    J Clin Oncol; 2008 Oct; 26(30):4973-80. PubMed ID: 18809608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens.
    Rosenberg SA; Zhai Y; Yang JC; Schwartzentruber DJ; Hwu P; Marincola FM; Topalian SL; Restifo NP; Seipp CA; Einhorn JH; Roberts B; White DE
    J Natl Cancer Inst; 1998 Dec; 90(24):1894-900. PubMed ID: 9862627
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel HLA-Cw8-restricted T cell epitopes derived from tyrosinase-related protein-2 and gp100 melanoma antigens.
    Castelli C; Tarsini P; Mazzocchi A; Rini F; Rivoltini L; Ravagnani F; Gallino F; Belli F; Parmiani G
    J Immunol; 1999 Feb; 162(3):1739-48. PubMed ID: 9973437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of MAGE, gp100 and tyrosinase genes in uveal melanoma cell lines.
    Luyten GP; van der Spek CW; Brand I; Sintnicolaas K; de Waard-Siebinga I; Jager MJ; de Jong PT; Schrier PI; Luider TM
    Melanoma Res; 1998 Feb; 8(1):11-6. PubMed ID: 9508371
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potent selection of antigen loss variants of B16 melanoma following inflammatory killing of melanocytes in vivo.
    Sanchez-Perez L; Kottke T; Diaz RM; Ahmed A; Thompson J; Chong H; Melcher A; Holmen S; Daniels G; Vile RG
    Cancer Res; 2005 Mar; 65(5):2009-17. PubMed ID: 15753401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I trial of interferon gamma retroviral vector administered intratumorally with multiple courses in patients with metastatic melanoma.
    Nemunaitis J; Fong T; Burrows F; Bruce J; Peters G; Ognoskie N; Meyer W; Wynne D; Kerr R; Pippen J; Oldham F; Ando D
    Hum Gene Ther; 1999 May; 10(8):1289-98. PubMed ID: 10365660
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paucity of functional T-cell memory to melanoma antigens in healthy donors and melanoma patients.
    Dhodapkar MV; Young JW; Chapman PB; Cox WI; Fonteneau JF; Amigorena S; Houghton AN; Steinman RM; Bhardwaj N
    Clin Cancer Res; 2000 Dec; 6(12):4831-8. PubMed ID: 11156242
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peptide vaccination of patients with metastatic melanoma: improved clinical outcome in patients demonstrating effective immunization.
    Markovic SN; Suman VJ; Ingle JN; Kaur JS; Pitot HC; Loprinzi CL; Rao RD; Creagan ET; Pittelkow MR; Allred JB; Nevala WK; Celis E
    Am J Clin Oncol; 2006 Aug; 29(4):352-60. PubMed ID: 16891861
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune and clinical outcomes in patients with stage IV melanoma vaccinated with peptide-pulsed dendritic cells derived from CD34+ progenitors and activated with type I interferon.
    Banchereau J; Ueno H; Dhodapkar M; Connolly J; Finholt JP; Klechevsky E; Blanck JP; Johnston DA; Palucka AK; Fay J
    J Immunother; 2005; 28(5):505-16. PubMed ID: 16113607
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single-step antigen loading and activation of dendritic cells by mRNA electroporation for the purpose of therapeutic vaccination in melanoma patients.
    Bonehill A; Van Nuffel AM; Corthals J; Tuyaerts S; Heirman C; François V; Colau D; van der Bruggen P; Neyns B; Thielemans K
    Clin Cancer Res; 2009 May; 15(10):3366-75. PubMed ID: 19417017
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.